OAKLAND PARK, FL--(Marketwired - Feb 1, 2016) - Dr. Dave Woynarowski was appointed Chief Medical Officer of Biostem Technologies, Inc. (OTC PINK: BSEM) effective immediately. Dr. Woynarowski received his medical degree from Temple University, and served as chief resident in his Internal Medicine Training program. He went on to become part of the resident education system, and twice receiving the prestigious Residents Teaching Award from his students and residents. He holds a Master's Degree in Physiology, and was a Certified Personal Trainer during his early medical career. He also served as Adjunct Professor to Hershey School of Medicine.
Dr. Woynarowski or more simply "Dr. Dave" as he is known to his patients has a background in Internal Medicine, and has been board certified in that discipline. He holds the A4M Anti-Aging medicine certification and was one of the first 30 physicians in the world to attain the AMA's certificate in Age Management Medicine. After practicing Internal Medicine for 15 years and Anti-Aging Medicine for 4 years he founded Dr. Dave's Best Nutraceuticals company in 2002 to fill the void in doctor designed nutraceuticals.
That company was acquired in November 2015 by Biostem Technologies, Inc. and Dr. Dave continues to direct its main functions including research and design.
Dr. Dave is also recognized as a worldwide expert on Telomeres and Telomerase. He has lectured on the topic multiple times to such groups as the A4M and AMMG.
In 2010 he wrote the first text book on Telomere biology for the non-scientist with co authors Dr. Mike Fossel and Greta Blackburn. Currently he is working on a second book which will include his expertise on other age related topics including stem cells and gene therapy.
On his transition to Biostem Technologies, Dr. Dave says, "This is actually a manifestation of a long term dream of mine. I have been working on developing a premier anti-aging team consisting of scientists, researchers, and entrepreneurs who are as dedicated to solving aging as I am. With that team now in place, I am excited to begin pursuing ideas that have been on hold for so long. We look forward to our ideas manifesting themselves into products and services that will help more people sooner!"
About Biostem Technologies, Inc. (BSEM):
Biostem Technologies (BSEM) is engaged in the advancement of regenerative medicine and anti-aging strategies throughout the United States, Europe, and Latin America. BSEM's goal is to deliver the highest standard wellness and stem cell products that are backed by science. Through scientific studies, we seek to become a world leader in the wellness arena. This will be accomplished by using the high quality nutraceuticals and stem cells. Our quest is to introduce the world, and our shareholders to our dedication to you and your well-being.
Mission Statement- Biostem Technologies is a Global Leader in Anti-Aging research. We are focused on advancing your quality of life, health span, and wellness.
Vision Statement- Biostem Technologies is a group of scientists, physicians, and visionaries creating the possibility of living life to its fullest. Our products and strategies are dedicated to helping you live your best, feel your best, and be your best.
Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," "believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.